{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004092","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.215778+00:00","generated_at":"2026-06-19T02:58:52.181166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning","bullets":["Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.","Full year 2022 revenue $1.6B, net income $515.8M ($3.89/share); cash & investments ~$2.4B.","CEO George Scangos retiring April 3, 2023; succeeded by Marianne De Backer (Bayer exec).","CFO Howard Horn resigning; replaced by Sung Lee, 20-year biotech veteran.","Key pipeline catalysts: HBV data H1 2023, influenza PENINSULA data mid-2023, HDV data H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004092","json":"https://secwatch.observer/filing/0000950170-23-004092.json","markdown":"https://secwatch.observer/filing/0000950170-23-004092.md","text":"https://secwatch.observer/filing/0000950170-23-004092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/vir-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:58:52.181166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07900d60863392e3d34bfa76f1b52c9f81af6ea7","claim":"Vir Biotechnology, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f6104d87cb69a65b0e92ddea87e3d953e05877a3","claim":"Vir Biotechnology, Inc. reported the full year ended December 31, 2022 results: revenue $1.5 billion.","evidence_excerpt":"– $1.5 billion of sotrovimab collaboration revenue recognized in 2022 –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$1.5 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}